Advaxis Reports Clinical Hold of Investigational Agent Axalimogene Filolisbac
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
FBR Capital Remains Bullish on Advaxis (ADXS) Following Conference Call About FDA IND Clinical Hold
October 7, 2015 7:49 AM EDTFBR Capital reiterated an Outperform rating and $34.00 price target on Advaxis (NASDAQ: ADXS) following a conference call and webcast. The call was to discuss the announcement that its Investigational New Drug (IND) application for axalimogene filolisbac (AF) was placed on clinical hold by the FDA, affecting four clinical trials with AF in cervical cancer.
Analyst Vernon Bernardino commented, "Advaxis, after market... More
